RE7

• Leaflet

Product description

PATENTED PRODUCT RE7 is a new, patented, liquid formulation of oral melatonin. The patent concerns the pharmaceutical technology called "Emuldrop®" where a fine micellar dispersion obtained thanks to surfactant agents incorporates the active ingredient, enhancing its sublingual and enteral absorption. With other melatonin based products, even of pharmaceutical grade, the oral bioavailability of melatonin is 2.5%; in RE7, thanks to the "Emuldrop" technology, it is showed a greater protection and a carrier of melatonin enhancing the gastric passage, increasing the bioavailability of the melatonin and making absorption faster. After 20 minutes, Emuldrop® melatonin has demonstrated 2 times higher absorption than normal melatonin, after 40 minutes, it showed 3 times higher absorption. RE7 is available in drops. The solution, preservative free, is in a practical 15 ml bottle with an internal dispenser. 5 drops of RE7 orally administered is equivalent to 1 mg of melatonin.

Composition

Stabilizer: Glycerol, Demineralized water; Emulsifiers: Polysorbate 80; Acidity regulators: Sodium bicarbonate; melatonin; Emulsifier: Conjugated linoleic acid

Preservation

• Keep the product at room temperature in a cool, dry place. • Avoid exposure to heat sources, sunlight and contact with water. • The shelf life refers to the product correctly stored, in unopened packaging. • Do not waste into the environment after use.